RUNX2/CBFB modulates the response to MEK inhibitors through activation of receptor tyrosine kinases in KRAS-mutant colorectal cancer

Intrinsic and acquired resistances are major hurdles preventing the effective use of MEK inhibitors for treatment of colorectal cancer (CRC). Some 35–45% of colorectal cancers are KRAS-mutant and their treatment remains challenging as these cancers are refractory to MEK inhibitor treatment, because...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Transl Oncol
Hlavní autoři: Šuštić, Tonći, Bosdriesz, Evert, van Wageningen, Sake, Wessels, Lodewyk F.A., Bernards, René
Médium: Artigo
Jazyk:Inglês
Vydáno: Neoplasia Press 2019
Témata:
Original article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6931198/
https://ncbi.nlm.nih.gov/pubmed/31865182
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.tranon.2019.10.006
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky